Dare Bioscience, Inc. (DARE)

Nasdaq: DARE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2007

Grade4.7

◀ Past 3.4● Present 3.4▶ Future 6.7

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Report filed	Mar 26, 2026	Mar 31, 2025	Mar 28, 2024	Mar 30, 2023	Mar 31, 2022	Mar 30, 2021	Mar 27, 2020	Apr 1, 2019	Mar 28, 2018	Mar 31, 2017
Revenue	1,030,193	9,784	2,807,885	10,000,000	0	·	·	·	·	766,000
Cost of revenue	295,799	0	·	·	·	·	·	·	·	·
Research and development	5,523,352	14,305,208^r	21,538,074	30,042,217	30,617,567	20,769,416	8,546,108	6,413,956	984,749	72,666^r
Selling, general and administrative	8,763,376	9,156,061	·	·	·	·	·	·	·	·
General and administrative	·	9,156,061	12,109,691	11,243,271	8,350,945	6,549,508	5,265,438	4,655,837	2,704,853	157,925^r
Total operating expenses	14,286,728	23,461,269	33,747,765	41,385,488	39,068,512	27,402,257	14,344,880	16,882,312	11,180,488	630,591^r
Operating income	-13,552,334	-23,451,485	-30,939,880	-31,385,488	-39,068,512	-27,402,257	-14,344,880	-16,882,312	-11,180,488	-630,591
Interest expense	·	·	·	·	·	·	·	·	322,629	42,096^r
Interest and investment income	·	·	·	·	·	·	·	·	·	86,000
Other income (expense), net	-153,060	981,490^r	778,489	437,750	2,520	1,514	81,050	143,497	-322,629	·
Total non-operating income (expense)	·	·	·	·	·	·	·	·	·	-2,151,000
Income before income taxes	-13,541,000	-4,052,000	-30,159,000	-30,948,000	-38,696,000	-27,401,000	-14,264,000	-16,814,000	-11,521,000	-673,000
Income tax expense	0	0	0	0	0	0	0	3,200	0	·
Net income	-13,399,274	-4,053,599	-30,161,391	-30,947,738	-38,696,105	-27,400,743	-14,263,830	-16,738,815	-11,503,117	-672,687^r
Net income to common shareholders	-13,399,274	-4,053,599	-30,161,391	-30,947,738	-38,696,105	-27,407,606	-15,053,424	-16,738,815	·	-39,305,000
Earnings per share, basic	-1.20	-0.48	-4.15^r	-4.44^b	-7.56^b	-10.92^b	·	·	·	·
Earnings per share, diluted	-1.20	-0.48	-4.15^r	-4.44^b	-7.56^b	-10.92^b	·	·	·	·
Earnings per share, basic and diluted	·	·	·	·	·	-10.92^b	-11.64^b	-18.84^rb	42.72^rb	-9.72^rb
Weighted average shares, basic	11,178,752	8,497,459	7,275,308^r	7,047,650^b	5,096,180^b	2,507,622^b	·	·	269,356^b	69,583^b
Weighted average shares, diluted	11,178,752	8,497,459	7,275,308^r	7,047,650^b	5,096,180^b	2,507,622^b	·	·	269,356^b	835,000
Weighted average shares, basic and diluted	·	·	·	·	·	2,507,622^b	1,298,247^b	894,368^b	269,356^b	2,309,200^b

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-12 reverse split of Jul 2024.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Revenue what customers paid for what it sold

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues

Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfRevenue

Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense

Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense

General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense

Total operating expenses the running costs togetherus-gaap:OperatingExpenses

Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss

Interest expense what its borrowing costus-gaap:InterestExpense

Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest

Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense

Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense

Income before income taxes profit before tax

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit

Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss

Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic

Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted

Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted

Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic

Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

SI Assistanton DARE · research, not advice